ESMO Media Releases

The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland tomorrow. 

ESMO announced today that it will be organising an annual Congress in Europe starting in 2016

A record number of 19,859 attendees at the ESMO 2014 Congress discussed changes to oncology that will soon have a positive impact on the care of patients around the world.

Corrigendum: Please note the updated data for the response rate is 52% instead of 43%

Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations

Important new data from two trials evaluating different treatment approaches in metastatic colorectal cancer provide reassurance for clinicians that current treatment choices are valid, and confirm that molecular characterisation of such tumours is vital

Dabrafenib anti-tumour activity in BRAF V600E mutation-positive non-small cell lung cancer; HER2 inhibition shows promise in HER2-positive non-small cell lung cancer

Preliminary data from a phase III trial suggest drug is well tolerated and leads to a sustained response in patients who have progressed after ipilimumab therapy

High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target

Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma. Phase III trial data shows better outcomes with combination therapy than vemurafenib alone.

Experts are divided on the value of lung cancer vaccination after disappointing results from the MAGRIT phase III trial.